New Data on Genzyme MS Drug Shows Improvement in Disability

Arlene Weintraub One of the most closely watched developments in the quest for new multiple sclerosis treatments is the experimental drug alemtuzumab (Lemtrada) from Cambridge, MA-based Genzyme, a unit of French drug giant Sanofi (NYSE: SNY).
Read the full story: Xconomy